No investor will be happy with their GSK shares as the FTSE 100 pharmaceutical giant has had a dismal decade. Will the next ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

"A regulatory decision by the FDA on this submission is expected in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including in the European Economic ...

(Alliance News) - DCC announced a deal to sell a part of its technology arm for GBP100 million, GSK is pursuing US approval for expanded use of its RSV jab, while South32 warned of an impairment at an ...

Sage, thank you for taking the time to speak with us today. What are the most promising industries you're seeing grow in our state right now?

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

GSK PLC closed 16.09% below its 52-week high of £16.79, which the company achieved on September 9th.